Reflections on the approach to treatment of a mycologic disaster

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1567-1572

  Stevens, David A ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; METHYLPREDNISOLONE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS FUMIGATUS; BACTERIAL ARTHRITIS; CANDIDA; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLADOSPORIUM; DRUG MEGADOSE; DRUG PENETRATION; DRUG TREATMENT FAILURE; EPIDEMIC; EPIDURAL ABSCESS; EXHEROHILUM ROSTRATUM; EXOPHIALA; FUNGAL MENINGITIS; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; MYCOSIS; NONHUMAN; NOTE; OSTEOMYELITIS; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHIZOPUS STOLONIFER; RHODOTORULA LARYNGIS; YEAST; ZYGOMYCETES;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CLADOSPORIUM; HUMANS; MUCORMYCOSIS; MYCOSES; PYRIMIDINES; RHIZOPUS; RHODOTORULA; TRIAZOLES;

EID: 84875167122     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02242-12     Document Type: Note

References (93)

1. Centers for Disease Control and Prevention. 2012. Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy-United States, 2012. MMWR Morbid. Mortal. Wkly. Rep. 61:839-842.
2. Centers for Disease Control and Prevention. 21 November2012. Interim treatment guidance for central nervous system and parameningeal infections associated with injection of contaminated steroid products. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hai/outbreaks/ clinicians/guidance-cns.html.
3. Revankar SG, Sutton DA. 2010. Melanized fungi in human disease. Clin. Microbiol. Rev. 23:884-928.
4. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. 2002. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis. 34:467-476.
5. Rai M, Bridge PD (ed). 2009. Applied mycology. CAB International, Wallingford, United Kingdom.
6. Sharkey PK, Graybill JR, Rinaldi MG, Stevens DA, Tucker RM, Peterie JD, Hoeprich PD, Greer D, Frenkel L, Counts G, Goodrich J, Zellner S, Bradsher RW, Van der Horst CM, Israel K, Pankey GA, Barranco CP. 1990. Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. 23:577-586.
7. Espinel-Ingroff A. 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39:954-958.
8. Espinel-Ingroff A, Boyle K, Sheehan DJ. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
9. Esser K (ed). 2008. The Mycota, human and animal relationships. VI. Springer, Berlin, Germany.
10. Radford SA, Johnson EM, Warnock DW. 1997. In vitro studies of activity of voriconazole (UK-104,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
11. Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. 2009. Phaeohyphomycosis in a tertiary care cancer center. Clin. Infect. Dis. 48:1033-1041.
12. Badali H, Najafzadeh MJ, Van Esbroeck M, van den Enden E, Tarazooie B, Meis JF, de Hoog GS. 2010. The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Med. Mycol. 48:318-327.
13. Espinel-Ingroff A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
14. Feng P, Najafzadeh MJ, Sun J, Ahmed S, Xi L, de Hoog GS, Lai W, Lu C, Klaasen CH, Meis JF. 2012. In vitro activities of nine antifungal drugs against 81 Phialophora and Cytellophora isolates. Antimicrob. Agents Chemother. 56:6044-6047.
15. Groll AH, Walsh TJ. 2001. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect. 7(Suppl 2):8-24.
16. Cassia da Cunha K, Sutton DA, Gene J, Capilla J, Cano J, Guarro J. 2012. Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exherohilum. Antimicrob. Agents Chemother. 56:4951-4954.
17. Rex JH, Stevens DA. 2009. Systemic antifungal agents, p 549-563. In Mandell GL, Dolin R, Bennett JE (ed), Principles and practice of infectious disease, 7th ed. Elsevier, Philadelphia, PA.
18. Denning DW, Hanson LH, Perlman AM, Stevens DA. 1992. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. 15:21-34.
19. Espinel-Ingroff A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
20. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Sentry Participants Group. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphothericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob. Agents Chemother. 46:1032-1037.
21. Verweij P, Snelders E, Kema GHJ, Mellado E, Melchers WJG. 2009. Azole resistance in Aspergillus fumigates: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
22. Kwon DS, Mylonakis E. 2007. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin. Pharmacother. 8:1167-1178.
23. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect Jr. 2003. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J. Clin. Microbiol. 41:5233-5235.
24. Schaffner A, Frick PG. 1985. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J. Infect. Dis. 151:902-910.
25. Cuenca-Estrella M. 2004. Combinations of antifungal agents in therapy-what value are they? J. Antimicrob. Chemother. 54:854-869.
26. Capilla J, Clemons KV, Stevens DA. 2007. Animal models: an important tool in mycology. Med. Mycol. 45:657-684.
27. Rivard RG, McCall S, Griffith ME, Hawley JS, Ressner RA, Borra H, Moon JE, Becklus ML, Murray CK, Hospenthal DR. 2007. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med. Mycol. 45:685-689.
28. Calvo E, Pastor FJ, Guarro J. 2010. Antifungal therapies in murine disseminated phaeohyphomycoses caused by Exophiala species. J. Antimicrob. Chemother. 65:1455-1459.
29. Calvo E, Pastor FJ, Salas V, Mayayo E, Capilla J, Guarro J. 2012. Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by Cladophialophora carrionii. J. Antimicrob. Chemother. 67:666-670.
30. Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D. 2004. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob. Agents Chemother. 48:2288-2291.
31. Al-Abdely HM, Najvar L, Bocanegra R, Fothergill A, Loenbenberg D, Rinaldi M, Graybill Jr. 2000. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob. Agents Chemother. 44:1159-1162.
32. Sugar AM, Liu X-P. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med. Mycol. 38:209-212.
33. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2005. Comparative efficacies of amphotericin B, AmBisome, caspofungin, micafungin and voriconazole alone and in combination against experimental murine CNS aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
34. Imai JK, Singh G, Clemons KV, Stevens DA. 2004. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48:4063-4066.
35. Chiller TM, Sobel RA, Capilla Luque J, Clemons KV, Stevens DA. 2003. The efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob. Agents Chemother. 47:813-815.
36. Clemons KV, Parmar R, Espiritu M, Stevens DA. 2006. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J. Antimicrob. Chemother. 58:466-469.
37. Sorensen KN, Sobel RA, Clemons KV, Pappagianis D, Stevens DA, Williams PL. 2000. Comparison of fluconazole and itraconazole in the treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob. Agents Chemother. 44:1512-1517.
38. Kamberi P, Sobel RA, Clemons KV, Waldvogel A, Striebel JM, Williams PL, Stevens DA. 2007. Comparison of itraconazole and fluconazole against coccidioidal meningitis in a murine model. Antimicrob. Agents Chemother. 51:998-1003.
39. Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. 2002. Efficacy of intravenous liposomal amphotericin against coccidioidal meningitis in rabbits. Antimicrob. Agents Chemother. 46:2420-2426.
40. Clemons KV, Capilla J, Sobel RA, Tong A-J, Martinez M, Stevens DA. 2009. Comparative efficacy of Abelcet and AmBisome against coccidioidal meningitis in rabbits. Antimicrob. Agents Chemother. 53:1858-1862.
41. Capilla J, Clemons KV, Stevens DA. 2007. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J. Antimicrob. Chemother. 60:673-676.
42. Boogaerts M, Maertens J. 2001. Clinical experience with itraconazole in systemic fungal infections. Drugs 61(Suppl 1):39-47.
43. Smith J, Safdar N, Knasinski V, Andes D. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
44. Thompson GR, Rinaldi MG, Pennis G, Dorsey SA, Patterson TF, Lewis JS. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
45. Slama T, Kauffman CA, Patterson TF, Neill MA. 2013. Fungal outbreak update from IDWeek. Clin. Infect. Dis. 56:621-624.
46. Kauffman CA, Pappas PG, Patterson TF. 19 October 2012. Fungal infections associated with contaminated methylprednisolone injections-preliminary report. N. Engl. J. Med. doi:10.1056/NEJMra1212617.
47. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. 1999. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J. Clin. Microbiol. 37:1186-1189.
48. Lutsar I, Roffey S, Troke P. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37:728-732.
49. Schwartz S, Thiel E. 2004. Update on the treatment of cerebral aspergillosis. Ann. Hematol. 83(Suppl 1):S42-S44.
50. Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. 2009. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant. 44:269-270.
51. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. 2011. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. J. Antimicrob. Chemother. 66:224-225.
52. Rüping MJGT, Albermann N, Ebinger F, Burckhardt I, Beisel C, Müller C, Vehreschild JJ, Kochanek M, Fatkenheuer G, Bangard C, Ullmann AJ, Herr W, Kolbe K, Hallek M, Cornely OA. 2008. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother. 62:1468-1470.
53. Tucker RM, Williams PL, Arathoon EG, Levine BE, Hartstein AI, Hanson LH, Stevens DA. 1988. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 32:369-373.
54. Perfect JR, Savani DV, Durack DT. 1986. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob. Agents Chemother. 29:579-583.
55. Tucker RM, Galgiani JN, Denning DW, Hanson LH, Graybill JR, Sharkey K, Eckman MR, Salemi C, Libke R, Klein RA, Stevens DA. 1990. Treatment of coccidioidal meningitis with fluconazole. Clin. Infect. Dis. 12(Suppl 3):S380-S389.
56. Tucker RM, Denning DW, Dupont B, Stevens DA. 1990. Itraconazole therapy of chronic coccidioidal meningitis. Ann. Intern. Med. 112:108-112.
57. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE, National Institute of Allergy and Infectious Diseases Mycoses Study Group Clinical Trials Group AIDS. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
58. Denning DW, Tucker RM, Hostetler JS, Gill S, Stevens DA. 1990. Itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS, p 305-324. In Vanden Bossche H, Mackenzie DWR, Cauwenbergh G, Drouhet E, Dupont B,Van Cutsem J (ed), Mycoses in AIDS patients. Plenum Press, New York, NY.
59. Matkham L, Garzoni C, Hirschel B, Harbarth S, Bouchuigui-Waf K, Garbino J. 2006. Is posaconazole a new treatment option for brain abscess? abstr p1212. Sixteenth European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 1 to 4 April 2006.
60. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. 2005. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med. Mycol. 43:91-95.
61. DeVita VT, Utz JP, Williams T, Carbone PP. 1966. Candida meningitis. Arch. Intern. Med. 117:527-535.
62. Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, Bansal E, Garner DC, Smith JA, Demicco DD, Schleupner CJ, Aldoghaither RA, Savaliya VA. 2013. Early clinical observations in prospectively followed patients with fungal meningitis related to contaminated epidural steroid injections. Ann. Intern. Med. doi:10.7326/0003-4819-158-3-201302050-00568.
63. Lewis RE. 2008. "What is the therapeutic range" for voriconazole? Clin. Infect. Dis. 46:212-214.
64. Clemons KV, Schwartz JA, Stevens DA. 2012. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, toxicity. Antimicrob. Agents Chemother. 56: 4439-4449.
65. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ. 2000. Comparative efficacy and distribution of lipid formulations of amphothericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282.
66. Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH. 2004. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin. Infect. Dis. 38:e15-e20.
67. Pittisuttithum P, Gaono-Flores V, Negroni R, Sanne I, Graybill JR, Bustamante A, Hare R, Hardalo C. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr M-978.
68. Negroni R, Tobón A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. 2005. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo 47:339-346.
69. Derber C, Elam K, Bearman G. 2010. Invasive sinonasal disease due to dematiaceous fungi in immunocompromised individuals: case report and review of the literature. Int. J. Infect. Dis. 14(Suppl 3):e329-e332.
70. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
71. Bulloch MN. 2011. The treatment of pulmonary Wangiella dermatitidis infection with oral voriconazole. J. Clin. Pharm. Ther. 36:433-436.
72. Criado PR, Careta MF, Valente NYS, Martins JEC, Rivitti EA, Spina R, Belda W. 2011. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J. Dermatolog. Treat. 22:167-174.
73. Centers for Disease Control and Prevention. 2002. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy-United States, July-November 2002. MMWR Morb. Mortal. Wkly. Rep. 51:1109-1112.
74. Fica A, Diaz M, Luppi M, Olivares R, Saez L, Baboor M, Vasquez P. 2003. Unsuccessful treatment with voriconazole of a brain abscess due to Cladophialophora bantiana. Scand. J. Infect. Dis. 35:892-893.
75. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer, the Global Aspergillus Study Group. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
76. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am. J. Med. 97:135-144.
77. Stevens DA, Lee JY. 1997. Analysis of compassionate use itraconazole therapy of invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch. Intern. Med. 157:1857-1862.
78. Walsh TJ, Raad I, Patterson TF, Chandrasekar C, Donowitz GR, Graybill JR, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Rebaud P, Segal BH, Stevens DA, van Burik JH, White CS, Corcoran G, Gogate J, Hardalo C, Krishna G, Pedicone L, Perfect Jr. 2007. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
79. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst H-A, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study Group. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (Am-BiLoad Trial). Clin. Infect. Dis. 44:1289-1297.
80. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ. 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26:1383-1396.
81. Sanchez C, Mauri E, Dalmau D, Quintana S, Aparicio A, Garau J. 1995. Treatment of cerebral aspergillosis with itraconazole: do high doses improve the prognosis? Clin. Infect. Dis. 21:1485-1487.
82. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106: 2641-2645.
83. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. 2011. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin. Infect. Dis. 53:1060-1066.
84. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, LAmph/ABLC Collaborative Study Group. 2000. A randomized, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31:1155-1163.
85. Kelly PC. 1980. Coccidioidal meningitis, p 163-193. In Stevens DA (ed), Coccidioidomycosis: a text. Plenum, New York, NY.
86. Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, Stevens DA. 1996. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124:305-310.
87. Stevens DA, Shatsky SA. 2001. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin. Respir. Infect. 16:263-269.
88. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagań o L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F. 1999. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin. Infect. Dis. 28:250-255.
89. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
90. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335- 347.
91. Schlamm H, Gao X, Ji X, Stephens J, Tavallo M. 2011. Economic evaluation of voriconazole versus itraconazole for primary prophylaxis of invasive fungal infection in allogeneic hematopoietic stem cell transplantation, abstr p2108. Twenty-first European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 7 to 10 May 2011.
92. Lat A, Thompson GR. 2011. Update on the optimal use of voriconazole for invasive fungal infections. Infect. Drug Resist. 4:43-53.
93. Ellis M, Bernsen R, Ali-Zadeh H, Kristensen J, Hedstrom U, Poughias L, Bresnik M, Al-Essa A, Stevens DA. 2009. A safety and feasibility study comparing intermittent high dose with a standard daily dose of liposomal amphotericin B for persistent neutropenic fever. J. Med. Microbiol. 58: 1474-1485.